Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 22 member 2 (SLC22A2), commonly known as Organic cation transporter 2 (OCT2), is a polyspecific transporter primarily located on the basolateral membrane of renal proximal tubule cells (UniProt P55018; NIH Gene ID 6582). It facilitates the electrogenic, sodium-independent uptake of a wide range of endogenous and exogenous organic cations from the blood into the kidney, serving as the rate-limiting step in their renal secretion (Wikipedia; Koepsell et al., 2007). Key substrates include endogenous compounds like creatinine and neurotransmitters such as dopamine and norepinephrine, as well as therapeutic agents like the antidiabetic drug metformin and platinum-based chemotherapeutics like cisplatin and oxaliplatin (PubMed; Motohashi et al., 2002). Due to its central role in drug disposition, OCT2 is a major site for clinically significant drug-drug interactions; inhibitors like cimetidine or dolutegravir can reduce the renal clearance of substrates, leading to increased systemic exposure and potential toxicity (Open Targets; Yee & Giacomini). Genetic polymorphisms in the SLC22A2 gene further contribute to inter-individual variability in drug response and susceptibility to adverse effects, such as cisplatin-induced nephrotoxicity and ototoxicity (ClinPGx; ResearchGate). Additionally, its expression levels in certain cancers, such as renal cell carcinoma, have been linked to patient survival and chemotherapy response (MDPI; Cancer Genome Atlas). Overall, OCT2 is a critical determinant of the pharmacokinetic profile and safety of many cationic drugs.
Facilitated diffusion of organic cations across the basolateral membrane of renal proximal tubule cells, mediating the first step of renal secretion.
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 22 member 2 (Organic cation transporter 2) (OCT2).